Berer A, Ohler L, Simonitsch I, Thalhammer R, Lechner K, Geissler K
First Department of Medicine, University of Vienna, Austria.
Wien Klin Wochenschr. 1999 Oct 15;111(19):815-8.
Current treatment of patients with myelodysplastic syndrome (MDS) is unsatisfactory. Very recently, immunosuppressive treatment strategies have been gaining interest. We report a patient with transfusion-dependent MDS who achieved significant hematopoietic improvement following cyclosporine (CsA) therapy and who is now transfusion independent for more than 5 years. This single observation supports the view that CsA, among other immunosuppressive agents, could play an important role in future treatment concepts in MDS and may lead to clinically relevant and sustained improvement of hematopoiesis in a subset of patients.
目前骨髓增生异常综合征（MDS）患者的治疗效果并不理想。最近，免疫抑制治疗策略越来越受到关注。我们报告了1例依赖输血的MDS患者，其在接受环孢素（CsA）治疗后造血功能得到显著改善，目前已5年以上无需输血。这一单独观察结果支持以下观点：在其他免疫抑制剂中，CsA在MDS未来的治疗理念中可能发挥重要作用，并且可能使一部分患者的造血功能得到临床相关且持续的改善。
